Hyperion DeFi (NASDAQ:HYPD) vs. Healios K.K. (OTCMKTS:HLOSF) Head-To-Head Analysis

Hyperion DeFi (NASDAQ:HYPD) and Healios K.K. (OTCMKTS:HLOSF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Hyperion DeFi and Healios K.K.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Healios K.K.	N/A	N/A	N/A

Earnings and Valuation

This table compares Hyperion DeFi and Healios K.K.”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$1.04 million	56.10	-$45.31 million	($9.95)	-0.39
Healios K.K.	N/A	N/A	N/A	($0.45)	-4.03

Healios K.K. has lower revenue, but higher earnings than Hyperion DeFi. Healios K.K. is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Hyperion DeFi and Healios K.K., as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2	0	1	1	2.25
Healios K.K.	0	0	0	0	0.00

Hyperion DeFi presently has a consensus price target of $5.88, suggesting a potential upside of 52.20%. Given Hyperion DeFi’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Hyperion DeFi is more favorable than Healios K.K..

Insider and Institutional Ownership

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 20.3% of Healios K.K. shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Hyperion DeFi beats Healios K.K. on 8 of the 11 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About Healios K.K.

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.